216 related articles for article (PubMed ID: 18623899)
41. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone.
Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW
J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467
[TBL] [Abstract][Full Text] [Related]
42. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study.
Delannoy A; Delabesse E; Lhéritier V; Castaigne S; Rigal-Huguet F; Raffoux E; Garban F; Legrand O; Bologna S; Dubruille V; Turlure P; Reman O; Delain M; Isnard F; Coso D; Raby P; Buzyn A; Caillères S; Darre S; Fohrer C; Sonet A; Bilhou-Nabera C; Béné MC; Dombret H; Berthaud P; Thomas X
Leukemia; 2006 Sep; 20(9):1526-32. PubMed ID: 16838024
[TBL] [Abstract][Full Text] [Related]
43. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Cohen MH; Farrell A; Justice R; Pazdur R
Oncologist; 2009 Feb; 14(2):174-80. PubMed ID: 19193781
[TBL] [Abstract][Full Text] [Related]
44. The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era.
Burke MJ; Willert J; Desai S; Kadota R
Pediatr Blood Cancer; 2009 Dec; 53(6):992-5. PubMed ID: 19621426
[TBL] [Abstract][Full Text] [Related]
45. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Nishii K; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Haematologica; 2008 Feb; 93(2):287-90. PubMed ID: 18223280
[TBL] [Abstract][Full Text] [Related]
46. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
47. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].
Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P
Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279
[TBL] [Abstract][Full Text] [Related]
48. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
[TBL] [Abstract][Full Text] [Related]
49. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
Payne SM; Kovacs MJ
Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
[TBL] [Abstract][Full Text] [Related]
50. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
Garg A; Duggal L; Aggarwal S; Jain N
J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
[TBL] [Abstract][Full Text] [Related]
51. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
52. [Imatinib-induced DRESS].
Goldman J; Duval-Modeste AB; Lambert A; Contentin N; Courville P; Musette P; Joly P
Ann Dermatol Venereol; 2008 May; 135(5):393-6. PubMed ID: 18457727
[TBL] [Abstract][Full Text] [Related]
53. [Targeted therapy of dermatofibrosarcoma with imatinib].
Ugurel S
J Dtsch Dermatol Ges; 2007 Mar; 5(3):261. PubMed ID: 17338806
[No Abstract] [Full Text] [Related]
54. Hypereosinophilic syndrome: diagnosis and treatment.
Peros-Golubicić T; Smojver-Jezek S
Curr Opin Pulm Med; 2007 Sep; 13(5):422-7. PubMed ID: 17940488
[TBL] [Abstract][Full Text] [Related]
55. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior.
McArthur GA
Curr Opin Oncol; 2006 Jul; 18(4):341-6. PubMed ID: 16721128
[TBL] [Abstract][Full Text] [Related]
56. Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Matsue K; Aoki T; Odawara J; Kimura S; Yamakura M; Takeuchi M
Leuk Res; 2009 Jun; 33(6):867-9. PubMed ID: 18951628
[No Abstract] [Full Text] [Related]
57. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results.
Malhotra B; Schuetze SM
Curr Opin Oncol; 2012 Jul; 24(4):419-24. PubMed ID: 22510939
[TBL] [Abstract][Full Text] [Related]
58. Imatinib: cardiac risks?
Prescrire Int; 2007 Apr; 16(88):72. PubMed ID: 17465036
[No Abstract] [Full Text] [Related]
59. Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
Li Y; Qiu L; Zou D; Zhao Y; Mi Y; Wang J
Ann Hematol; 2009 Nov; 88(11):1069-77. PubMed ID: 19277658
[TBL] [Abstract][Full Text] [Related]
60. Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST.
Pitini V; Arrigo C; Sauta MG; Altavilla G
Leuk Res; 2009 Sep; 33(9):e143-4. PubMed ID: 19443031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
